FDG-PET/CT combined with CTC might better ID new cancer cells

08/26/2010 | AuntMinnie.com (free registration)

Circulating tumor cell counts corresponded with results of FDG-PET/CT tests in determining nonprogressive or progressive disease in 78% of patients with bone metastases from breast cancer, a study published in the Journal of Nuclear Medicine showed. "The combination of FDG-PET/CT and CTC might be a useful tool to monitor response to therapy in patients without measurable extraosseous disease, especially in patients with elevated CTC at baseline," the researchers said.

View Full Article in:

AuntMinnie.com (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Corporate Counsel - Regulatory Law
Regeneron
Tarrytown, NY
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
Senior Attorney
Blue Cross Blue Shield of Louisiana
Baton Rouge, LA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI